Renaissance Technologies LLC Sells 559,600 Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR)

Renaissance Technologies LLC cut its holdings in Kezar Life Sciences, Inc. (NASDAQ:KZR) by 41.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 778,474 shares of the company’s stock after selling 559,600 shares during the period. Renaissance Technologies LLC owned approximately 1.07% of Kezar Life Sciences worth $467,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Fidelis Capital Partners LLC bought a new stake in shares of Kezar Life Sciences in the 1st quarter worth approximately $25,000. Marquette Asset Management LLC purchased a new position in Kezar Life Sciences during the 1st quarter valued at $114,000. BNP Paribas Financial Markets raised its holdings in Kezar Life Sciences by 35.4% in the 1st quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock worth $247,000 after purchasing an additional 71,543 shares in the last quarter. Ikarian Capital LLC lifted its position in shares of Kezar Life Sciences by 1.8% in the 1st quarter. Ikarian Capital LLC now owns 868,992 shares of the company’s stock worth $783,000 after purchasing an additional 15,601 shares during the period. Finally, Acuitas Investments LLC boosted its stake in shares of Kezar Life Sciences by 42.8% during the 2nd quarter. Acuitas Investments LLC now owns 986,785 shares of the company’s stock valued at $592,000 after purchasing an additional 295,956 shares in the last quarter. 67.90% of the stock is owned by institutional investors.

Kezar Life Sciences Price Performance

Shares of KZR stock opened at $0.85 on Friday. The business’s fifty day moving average is $0.63 and its 200 day moving average is $0.69. The company has a quick ratio of 9.58, a current ratio of 9.58 and a debt-to-equity ratio of 0.05. The stock has a market cap of $62.14 million, a price-to-earnings ratio of -0.61 and a beta of 0.21. Kezar Life Sciences, Inc. has a twelve month low of $0.52 and a twelve month high of $1.14.

Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. Research analysts expect that Kezar Life Sciences, Inc. will post -1.2 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating on shares of Kezar Life Sciences in a report on Wednesday, October 2nd.

Kezar Life Sciences Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.